麻豆传媒

Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan

However, plinabulin plus docetaxel still "not ready for prime time," expert says

Absolute improvement of almost 30%, doubling of duration of response with savolitinib

Two-trial analysis shows about a 40% decreased risk of disease recurrence or death

Novel agent nearly halved risk of progression as first-line therapy in phase III trial

Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy

In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity

Alternate criteria based on years of smoking has higher sensitivity and specificity, study says

Lazertinib plus amivantamab improved PFS by about 7 months versus single-agent osimertinib

More data for discussion of controversial association between steroids, immunotherapy

PD-L1 checkpoint inhibitor approved for use in NSCLC before and after surgery

Colorectal cancer screening accounted for 64% of the total amount

Committee unanimously backs mandating trial design to distinguish effects of therapy phases

"Former smokers who use e-cigarettes remain at increased risk of lung cancer," researchers say